Literature DB >> 2545925

Neutralizing monoclonal antibodies against three serotypes of porcine rotavirus.

H S Nagesha1, L E Brown, I H Holmes.   

Abstract

Using three serotypes (four strains) of cultivable porcine rotavirus as immunizing antigens, 10 neutralizing monoclonal antibodies were characterized. One VP4-specific monoclonal antibody directed against porcine rotavirus BEN-144 (serotype G4) neutralized human rotavirus strain ST-3 in addition to the homologous porcine virus. All nine VP7-specific monoclonal antibodies were highly specific for viruses of the same serotype as the immunizing rotavirus strain. One exception was the VP7-specific monoclonal antibody C3/1, which neutralized both serotype G3 and G5 rotaviruses. However, this monoclonal antibody did not neutralize the porcine rotavirus AT/76, also of serotype G3, nor mutants of SA-11 virus (serotype G3) which were selected with monoclonal antibody A10/N3 and are known to have mutations affecting the C antigenic region.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545925      PMCID: PMC250936          DOI: 10.1128/JVI.63.8.3545-3549.1989

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Derivation of neutralizing monoclonal antibodies to human rotaviruses and evidence that an immunodominant neutralization site is shared between serotypes 1 and 3.

Authors:  B S Coulson; J M Tursi; W J McAdam; R F Bishop
Journal:  Virology       Date:  1986-10-30       Impact factor: 3.616

2.  Simple and specific enzyme immunoassay using monoclonal antibodies for serotyping human rotaviruses.

Authors:  B S Coulson; L E Unicomb; G A Pitson; R F Bishop
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

3.  Demonstration of an immunodominant neutralization site by analysis of antigenic variants of SA11 rotavirus.

Authors:  I Lazdins; S Sonza; M L Dyall-Smith; B S Coulson; I H Holmes
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

4.  Rotavirus isolate WI61 representing a presumptive new human serotype.

Authors:  H F Clark; Y Hoshino; L M Bell; J Groff; G Hess; P Bachman; P A Offit
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

5.  Glycosylation, an important modifier of rotavirus antigenicity.

Authors:  J Caust; M L Dyall-Smith; I Lazdins; I H Holmes
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

6.  The major surface glycoprotein of simian rotavirus (SA11) contains distinct epitopes.

Authors:  S Sonza; A M Breschkin; I H Holmes
Journal:  Virology       Date:  1984-04-30       Impact factor: 3.616

7.  Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity.

Authors:  Y Hoshino; M M Sereno; K Midthun; J Flores; A Z Kapikian; R M Chanock
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

8.  New porcine rotavirus serotype antigenically related to human rotavirus serotype 3.

Authors:  H S Nagesha; I H Holmes
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

9.  Analysis by plaque reduction neutralization assay of intertypic rotaviruses suggests that gene reassortment occurs in vivo.

Authors:  Y Hoshino; M M Sereno; K Midthun; J Flores; R M Chanock; A Z Kapikian
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

10.  Antigenic mapping of the surface proteins of rhesus rotavirus.

Authors:  R D Shaw; P T Vo; P A Offit; B S Coulson; H B Greenberg
Journal:  Virology       Date:  1986-12       Impact factor: 3.616

View more
  10 in total

1.  Evidence for two serotype G3 subtypes among equine rotaviruses.

Authors:  G F Browning; R M Chalmers; T A Fitzgerald; D R Snodgrass
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

2.  Operational overlapping of cross-reactive and serotype-specific neutralization epitopes on VP7 of human rotavirus serotype 3.

Authors:  N Kobayashi; K Taniguchi; S Urasawa
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

3.  Rotavirus replication in intestinal cells differentially regulates integrin expression by a phosphatidylinositol 3-kinase-dependent pathway, resulting in increased cell adhesion and virus yield.

Authors:  Peter Halasz; Gavan Holloway; Stephen J Turner; Barbara S Coulson
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

4.  Typing of human rotavirus VP4 by an enzyme immunoassay using monoclonal antibodies.

Authors:  B S Coulson
Journal:  J Clin Microbiol       Date:  1993-01       Impact factor: 5.948

5.  Comparative sequence analysis of VP7 genes from five Australian porcine rotaviruses.

Authors:  J Huang; H S Nagesha; M L Dyall-Smith; I H Holmes
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

6.  VP4 relationships between porcine and other rotavirus serotypes.

Authors:  H S Nagesha; I H Holmes
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

7.  Cross-reactive, serotype- and monotype-specific neutralization epitopes on VP7 of serotype G3 and G5 porcine rotavirus strains.

Authors:  M Ciarlet; M Hidalgo; F Liprandi
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

8.  Characterization of the neutralizing epitopes of VP7 of the Gottfried strain of porcine rotavirus.

Authors:  S Y Kang; D A Benfield; M Gorziglia; L J Saif
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

9.  Integrin-using rotaviruses bind alpha2beta1 integrin alpha2 I domain via VP4 DGE sequence and recognize alphaXbeta2 and alphaVbeta3 by using VP7 during cell entry.

Authors:  Kate L Graham; Peter Halasz; Yan Tan; Marilyn J Hewish; Yoshikazu Takada; Erich R Mackow; Martyn K Robinson; Barbara S Coulson
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Molecular and serological analyses of two bovine rotaviruses (B-11 and B-60) causing calf scours in Australia.

Authors:  J A Huang; H S Nagesha; D R Snodgrass; I H Holmes
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.